No Data
Shenzhou Cell (688520.SH): The company has not laid out in the development of new stem cell products and regenerative medicine.
On November 15, Gelonghui reported that Shenzhou Cell (688520.SH) investor relations activity record shows that the company has no layout in stem cell new product development and regenerative medicine.
Shenzhou Cell (688520.SH): The SCT-I10A monoclonal antibody has two indications for liver cancer and head and neck cancer in the market approval stage.
Gelonghui November 15th 丨 Investor Relations Activity Record of Shenzhou Cell (688520.SH) shows that SCT-I10A monoclonal antibody has two indications for liver cancer and head and neck cancer in the market approval stage, with no other indications currently planned for market approval.
Shenzhou Cell (688520.SH): Plans to conduct perpetual bond financing of no more than 0.8 billion yuan with its controlling shareholder, Lasa Ailik.
Gelonghui November 15th | The investor relations activity record of Shenzhou Cell (688520.SH) shows that the company plans to conduct perpetual debt financing of no more than 0.8 billion yuan to the controlling shareholder Lhasa Ailik. The proposal for this perpetual debt financing has been approved at the twelfth meeting of the second session of the board of directors and the second extraordinary general meeting of shareholders in 2024. The perpetual debt financing funds are expected to be in place by the end of 2024, which will guarantee the company's net assets turning positive.
Shenzhou Cell (688520.SH): The subjects of the 14-valent HPV vaccine have completed the third dose, and are currently in the follow-up stage.
Gelonghui November 15th | Shenzhou Cell (688520.SH) Investor Relations Activity Record Form shows that the 14-valent HPV vaccine recipients have completed the third dose, are currently in the follow-up stage, and related research and data analysis are voluntary disclosure information by the company. The company will disclose information in accordance with laws and regulations based on business progress.
Sinocelltech Group Limited (SHSE:688520) About To Shift From Loss To Profit
Shenzhou Cell: Shenzhou Cell 2024 Third Quarter Report
Subdued Growth No Barrier To Sinocelltech Group Limited's (SHSE:688520) Price
No Data
